A viable organ engineering pipeline requires the mass production of hundreds of billions of cells, tailorable and programmable cellular composition, and technologies to assemble these cells with perfusable vascular networks to support cell viability. Dr. Mark Skylar-Scott's lab is developing integrative technologies, including wetware, hardware, and software, to address cardiac tissue engineering at whole-organ scale.

The Wernig lab is generally interested in the mechanisms that determine cell fate identity.

Dr. Buckwalter's laboratory's goal is to improve how people recover after a stroke.

Dr. Barna's lab studies how intricate control of gene expression and cell signaling is regulated on a minute-by-minute basis to give rise to the remarkable diversity of cell types and tissue morphology that form the living blueprints of developing organisms.